Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | FABP6 | P51161 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27444970 | 0.90 | PARP1 (0.41) | ALDH1A1GAAHSD17B10MAPTPARP1 | |
| SCHEMBL18087622 | 0.87 | GAA (0.44) | ALDH1A1GAAHSD17B10MAPTPARP1 | |
| SCHEMBL19772859 | 0.87 | ALDH1A1 (0.46) | ALDH1A1GAAHSD17B10MAPTGRM5 | |
| SCHEMBL8433820 | 0.86 | ALDH1A1 (0.62) | ALDH1A1GAAHSD17B10MAPTPARP1 | |
| SCHEMBL22912275 | 0.83 | ALDH1A1 (0.45) | ALDH1A1GAAHSD17B10MAPTGRM5 | |
| SCHEMBL14367263 | 0.82 | PARP1 (0.45) | ALDH1A1GAAPARP1KDM4EHPGD | |
| SCHEMBL25107140 | 0.82 | ALDH1A1 (0.45) | ALDH1A1GAAHSD17B10MAPTGRM5 | |
| SCHEMBL18522454 | 0.82 | ALDH1A1 (0.45) | ALDH1A1GAAHSD17B10MAPTGRM5 | |
| SCHEMBL18594591 | 0.82 | ALDH1A1 (0.45) | ALDH1A1GAAHSD17B10MAPTGRM5 | |
| SCHEMBL21102115 | 0.80 | ALDH1A1 (0.43) | ALDH1A1GAAHSD17B10MAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151833-A1 | SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF | CEREVEL THERAPEUTICS, LLC (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-01 | — | — | US | disclosed |
| US-10730877-B2 | 4-Azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-26 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | Schering Corporation Patent Department, K-6-1; 1990 (US) | 2010-11-11 | — | — | US | disclosed |
| US-7759339-B2 | Hydroxysteroid dehydrogenase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| US-20080070910-A1 | Therapeutic compounds and methods | GILEAD SCIENCES, INC. | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | ALDH1A1 4344/4885GAA 2777/4885HSD17B10 3229/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885GAA 145/4885HSD17B10 205/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | ALDH1A1 550/4885GAA 910/4885HSD17B10 110/4885 |
| US-20100286135-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MTOR, CDK1, MAP3K8 | ALDH1A1 2293/4885GAA 1462/4885HSD17B10 1408/4885 |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | ALDH1A1 4344/4885GAA 2777/4885HSD17B10 3229/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2100/4885GAA 3287/4885HSD17B10 4655/4885 |
| US-10730877-B2 | 4-Azaindole compounds | TLR7, TLR9, TLR5 | ALDH1A1 1039/4885GAA 2277/4885HSD17B10 4116/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ALDH1A1 2100/4885GAA 3287/4885HSD17B10 4655/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | ALDH1A1 1840/4885GAA 170/4885HSD17B10 3082/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 482/4885GAA 145/4885HSD17B10 205/4885 |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | ALDH1A1 1039/4885GAA 2277/4885HSD17B10 4116/4885 |
| US-20230159509-A1 | PYRIDINESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, PPM1D | ALDH1A1 2592/4885GAA 1682/4885HSD17B10 3166/4885 |
| US-20200308172-A1 | SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR1, TLR7, TLR9 | ALDH1A1 1511/4885GAA 2507/4885HSD17B10 3848/4885 |
| US-20080070910-A1 | Therapeutic compounds and methods | SERPINB1, ABCC1, SERPINB6 | ALDH1A1 1840/4885GAA 170/4885HSD17B10 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.